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ABSTRACT 
 
c-Myb is an essential hematopoietic transcription factor that controls proliferation and 
differentiation of progenitors during blood cell development. Whereas sumoylation of the C-
terminal regulatory domain (CRD) is known to have a major impact on the activity of c-Myb, no 
role for non-covalent binding of SUMO to c-Myb has been described. Based on the consensus 
SUMO-interacting motif (SIM) we identified and examined putative SIMs in human c-Myb. 
Interaction and reporter assays showed that the SIM in the in the transactivation domain of c-Myb 
(V267NIV) is functional. This motif is necessary for c-Myb to be able to interact non-covalently 
with SUMO, preferentially SUMO2/3. Destroying the SUMO binding properties by mutation 
resulted in a large increase in the transactivation potential of c-Myb. Mutational analysis and 
overexpression of conjugation-defective SUMO argued against intramolecular repression caused 
by sumoylated CRD and in favour of SUMO-dependent repression in trans. Using both a 
myeloid cell line-based assay and a primary hematopoietic cell assay, we addressed the 
transforming abilities of SUMO binding and conjugation mutants. Interestingly, only loss of 
SUMO binding, and not SUMO conjugation, enhanced the myeloid transformational potential of 
c-Myb. c-Myb with the SIM mutated conferred a higher proliferative ability than the wild-type 
and caused an effective differentiation block. This establishes SUMO binding as a mechanism 
involved in modulating the transactivation activity of c-Myb, and responsible for keeping the 
transforming potential of the oncoprotein in check. 
 
Keywords:  c-Myb, SUMO, SUMO-interacting motif, myeloid, transformation, hematopoiesis 
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INTRODUCTION 
 
SUMO (Small Ubiquitin-like modifier) has emerged as a major regulator of a host of cellular 
processes, and the number of targeted proteins is constantly growing (Geiss-Friedlander and 
Melchior 2007). Covalent conjugation of SUMO to nuclear factors mainly suppresses their 
activity and/or ability to synergize with other factors, alters their localization and interaction 
repertoire, or increases their stability (Gill 2005, Hay 2005, Kerscher et al 2006). With the 
increasing number of sumoylated targets, and the common assumption that the effects of SUMO 
must be mediated through protein interactions, the identification of a protein motif for non-
covalent SUMO binding was awaited. In 2004 Song and co-workers showed using NMR that a 
small hydrophobic patch, V/I-X-V/I-V/I, was the minimal motif needed for SUMO interaction 
(Song et al 2004). This only partly matched a motif proposed earlier (Minty et al 2000). 
However, with the work of Hannich et al (2005) and Hecker et al (2006), the suggested 
consensus sequences were harmonized to V/I-X-V/I-V/I-a-a-a (a=acidic). Furthermore, the motif 
was shown to be able to bind to SUMO when reversed (Hecker et al 2006, Song et al 2005). The 
discovery of SUMO-interacting motifs (SIMs) has provided new insight into the interplay 
between sumoylation and SUMO binding, with the tumour suppressor PML as one of the best 
studied examples (Lallemand-Breitenbach et al 2008, Lin et al 2006, Shen et al 2006). The PML 
protein contains both sumoylation and SUMO-interacting motifs, and both motifs must be intact 
to form PML nuclear bodies (Shen et al 2006). 
c-Myb is a sequence-specific transcription factor that controls proliferation and differentiation 
of early hematopoietic progenitor cells, as well as regulating similar processes in colonic crypts 
and neurogenic regions of the adult brain (Ramsay and Gonda 2008). The MYB locus is 
rearranged in several human neoplasias, with increased expression as a frequent outcome. This 
can be caused by translocation, leading to deregulation of the MYB gene, as in childhood T cell 
acute lymphoblastic leukemia (T-ALL) (Clappier et al 2007), or stabilisation of MYB mRNA, as 
in adenoid cystic carcinomas (ACC) of the breast, head and neck (Persson et al 2009). Local 
duplication of MYB has also been reported with another subgroup of T-ALL (Clappier et al 2007, 
Lahortiga et al 2007) and in a subgroup of acute myelomonocytic leukemia (AML) (Murati et al 
2009). Thus, deregulation of c-Myb expression is associated with oncogenicity. Moreover, Myb’s 
transcriptional regulatory activity is crucial for its transforming ability (Gonda et al 1989, Hu et 
al 1991, Lane et al 1990). Multiple co-factors like p300/CBP, Mi-2α, FLASH, and menin/MLL 
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engage in the regulation of the transactivational activity of c-Myb (Alm-Kristiansen et al 2008, 
Dai et al 1996, Jin et al 2010, Kasper et al 2002, Oelgeschlager et al 1996, Saether et al 2007). 
Recently, the importance of co-activation by p300 in myeloid transformation was highlighted 
employing a novel murine hematopoietic cell line transformation assay (Pattabiraman et al 2009). 
Moreover, the interaction between Myb and menin/MLL has been shown to be a critical driver in 
MLL-associated leukemogenesis (Jin et al 2010). 
c-Myb becomes sumoylated in its C-terminal regulatory domain (CRD) at two sites, by both 
SUMO1 and SUMO2/3. This leads to a severe drop in the activity of c-Myb (Bies et al 2002, 
Dahle et al 2003, Sramko et al 2006). We have recently shown that this drop in activity is mainly 
due to silencing of a SUMO-regulated activation function in CRD, severely reducing the 
synergistic potential of c-Myb (Molvaersmyr et al 2010). In the oncogenic v-Myb protein, both 
SUMO conjugation sites are deleted and synergy control is lost. Whether loss of SUMO 
regulation is a central step in oncogenic activation of c-Myb has so far not been addressed. 
In this paper we show that the transactivation potential of c-Myb is modulated not only 
through SUMO conjugation, but also through non-covalent SUMO binding. We have identified a 
functional SIM in the transactivation domain of c-Myb, which preferentially binds SUMO2/3. 
Abrogation of SUMO binding through mutation leads to an increase in c-Myb transactivational 
activity, mainly caused by lost repression in trans. Through the use of hematopoietic 
transformation assays, we show that loss of SUMO regulation can oncogenically activate c-Myb. 
However, only loss of SUMO binding, and not SUMO conjugation, unleashes the transforming 
potential of c-Myb. 
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RESULTS 
 
c-Myb contains two putative SUMO interacting motifs 
AMV v-Myb is one of two oncogenically activated forms of c-Myb known to cause acute 
leukemia in chickens. Deletions in the v-myb gene eliminate the C-terminal regulatory domain 
(CRD; Figure 1a), making v-Myb behave like an activated form of c-Myb in many assays with 
lost SUMO conjugation playing a key role (Dahle et al 2003). We recently realized that loss of 
SUMO conjugation sites might not be the only oncogenic alteration in v-Myb that relates to 
SUMO biology. Based on reports of a consensus SUMO-interacting motif (SIM; aaa-V/I-V/I-X-
V/I/L and V/I-X-V/I-V/I-aaa) (Hecker et al 2006, Song et al 2004), we analysed the c-Myb 
sequence and found that it contains two putative SIMs; one in the R2 repeat in the DNA-binding 
domain (M1), and one in the N-terminal end of the transactivation domain (M2; Figures 1a and 
b). Both sites are evolutionarily well conserved, and remarkably, both are mutated in AMV v-
Myb (Figure 1b). In fact, three of the ten oncogenic mutations in v-Myb are localized to the 
putative SIMs. The specificity of non-covalent SUMO1 versus SUMO2 binding lies in a stretch 
of negatively charged residues located directly N- or C-terminally of the core SIM motif (Hecker 
et al 2006). The fact that only M1 has such neighbouring residues implies that if functional, the c-
Myb M1 would be a SUMO1-interacting motif, while M2 would mainly interact with SUMO2/3. 
 
Destroying the putative SIM in the transactivation domain by mutations derepresses c-Myb  
To investigate whether mutations in these potential SIMs would influence c-Myb activity, we 
made a set of mutants aiming to abrogate SUMO binding (Figure 1c). The mutants L106H and 
I267NII were made to mimic the mutations found in v-Myb M1 and M2, respectively. However, 
since only the L106H mutation represented a deviation from the SIM consensus, additional 
mutations A103AEA (wild type: V103IEL) and A267NAA (wild type: V267NIV) were introduced to 
ensure a complete elimination of SUMO binding to these motifs. 
We then performed effector-reporter assays using a c-Myb-responsive luciferase reporter. As 
can be seen in Figure 2a, the M1 mutant L106H had no effect, while the A103AEA appeared to 
have a slight negative influence on c-Myb-mediated transactivation. On the other hand, the 
A267NAA M2 mutant had a dramatic effect and activated c-Myb more than 13-fold relative to the 
wild-type. The activity of this mutant closely resembled that of the SUMO conjugation negative 
2KR mutant (Dahle et al 2003), used as a positive control (Figure 2a). The v-Myb mimicking 
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mutation I267NII had no such derepression effect; rather, it slightly lowered the activity of c-Myb. 
As can be seen in Figure 2b, none of these effects can be attributed to mutation-induced changes 
in protein expression levels. It therefore appears that the V267NIV motif in c-Myb TAD has a 
strong suppressive function on activity, possibly mediated through the binding of SUMO, and 
that the A267NAA mutant abrogates this suppression. 
 
Human c-Myb binds SUMO via a SIM in the transactivation domain 
To examine whether c-Myb was able to bind SUMO, we asked whether c-Myb could be pulled 
down from cell lysates using GST-SUMO1 and -SUMO2. This is currently one of the most 
stringent ways of detecting SUMO interactions, allowing both endogenous SUMO and SUMO- 
binding factors to compete for epitopes. SUMO, in general, binds to SIMs with affinities in the 
μM range (Hecker et al 2006), making the interaction somewhat difficult to detect. To avoid 
potential interference from SUMO moieties conjugated to c-Myb, we used a shortened version of 
human c-Myb (aa 1-409) where the CRD (harbouring the SUMO conjugation motifs) had been 
deleted. As can be seen in Figure 3a, c-Myb bound SUMO under these conditions. Furthermore, 
it seemed to interact more efficiently with SUMO2 than with SUMO1. 
In order to determine which of the motifs might be responsible for the non-covalent binding 
of SUMO, we evaluated the different mutants in pull-down assays. Comparison of c-Myb wild-
type with the M1 mutants (L106H and A103AEA), did not reveal any difference in the affinity for 
SUMO (Figure 3b); both proteins interacted with SUMO2, and thus resembled the wild-type. In 
contrast, an obvious difference was observed when comparing the M2 mutants (A267NAA and 
I267NII) with the wild-type (Figure 3c). While the I267NII mutant seemed to have retained the 
ability of c-Myb to bind SUMO, the A267NAA mutant had lost this property. Importantly, we 
could also show that full-length c-Myb, like the shorter version, was retained with GST-SUMO2 
(Figure 3d). Moreover, the M2 mutation ANAA lowered the affinity for SUMO2 substantially. 
Finally, we tried to study the interaction between SUMO and c-Myb, expressed at endogenous 
levels in erythroleukemia K562 cells. As expected, due to the low SIM Kd, only minute, but 
detectable, amounts of c-Myb was retained with GST-SUMO (Supplementary Figure 1). 
The mutations found in the putative SIMs in v-Myb (L106H and INII) did not cause any 
major change in the SUMO binding properties of c-Myb (Figures 3c and d). In line with this v-
Myb showed the same SUMO binding characteristics as c-Myb, including the preferred binding 
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to SUMO2 (Supplementary Figure 2). The same pattern emerged when using in vitro translated, 
[35S]-labelled c-Myb as prey in pull-down assays (Supplementary Figure 3), but no SUMO 
preference was apparent in this setting. Some of these experiments were conducted in the 
presence or absence of ethidium bromide or DNA containing Myb-binding sites. None of these 
experiments indicated that an engaged DNA-binding domain changed the interaction between c-
Myb and SUMO (data not shown). 
 
Abrogating SUMO binding affects sumoylation of c-Myb 
The evidence presented above show a physical, non-covalent interaction between SUMO and the 
c-Myb SIM, V267NIV. Moreover, a derepression of c-Myb activity was observed with the 
A267NAA mutant. Because the latter effect resembled that of the SUMO conjugation-disrupting 
2KR mutations, we asked whether derepression by the ANAA mutation might be caused by 
SUMO conjugation being dependent on a functional SIM as previously shown for TDG, Daxx 
and SP100 (Knipscheer et al 2008, Lin et al 2006, Takahashi et al 2005). The two SIM mutants 
(A267NAA and I267NII) were expressed in CV-1 cells in absence or presence of the SUMO E2 
conjugating enzyme Ubc9 or the SUMO E3 ligase PIASy increasing the relative amount of 
sumoylated c-Myb, and the sumoylation patterns were compared with those of c-Myb wild-type 
(two mono- + one disumoylated form) and 2KR (no sumoylated forms) (Figure 4). As can be 
seen in Figure 4a, the level of sumoylated c-Myb was lowered when the SIM consensus was lost 
(ANAA). The INII mutant on the other hand seemed to be sumoylated with the same efficiency 
as wild-type c-Myb. The reduced sumoylation efficiency seen with the ANAA mutant was 
persistent and could be seen when both E2 and E3 were overexpressed (Figure 4a). Nevertheless, 
c-Myb ANAA was modified, although at lower levels; this contrasts with c-Myb 2KR where 
SUMO conjugation was lost. We conclude that SUMO binding has a modulating effect on 
SUMO conjugation, without it being able to explain the high transactivational activity of the 
ANAA mutant. 
 
Functional effects of altered SUMO interaction in the absence of SUMO conjugation 
Previous studies have reported the existence of intramolecular interactions between the EVES 
domain and the N-terminal region of c-Myb (Dash et al 1996). Moreover, others have speculated 
that there might be an indirect contact between the CRD and the TAD (Dubendorff et al 1992, 
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Vorbrueggen et al 1994). Thus, we asked whether SUMO conjugates in the CRD and the SUMO-
interacting motif in the TAD might interact to bridge these parts of c-Myb. We reasoned that if 
SUMO conjugation and SUMO binding were part of the same mechanism in c-Myb, destroying 
either one or both of these functions would lead to a similar enhancement of transactivation. As 
shown in Figures 2a and 5a, c-Myb A267NAA and c-Myb 2KR possess almost identical activities. 
However, when both these mutations were introduced in the same construct (c-Myb ANAA 
2KR), an additive increase in activity was observed (Figure 5a), arguing against these two 
mutants targeting the same mechanism. Even when the entire CRD was deleted, the A267NAA 
mutation still increased the activity of c-Myb (Figure 5b). Thus, we conclude that the 
transactivation potential unleashed by the SIM mutation in c-Myb is disconnected from SUMO 
conjugation in the EVES domain. Even though the SUMO-interacting motif might be involved in 
recruiting or orienting components of the sumoylation apparatus, the SIM clearly also has a 
conjugation-independent function. 
To make sure that what we had observed so far was also relevant for regulation of c-Myb-
dependent activation of an endogenous chromatin-embedded gene, we tested the mutants for their 
ability to activate mim-1 (Burk et al 1993, Ness et al 1993), using real-time PCR. Mutation of the 
SUMO-interacting motif in c-Myb resulted in significant increase in expression of mim-1, both 
alone and in combination with the 2KR mutation (Figure 5c). To ensure that the increased 
transactivational activity of the SUMO binding mutant was not caused by altered DNA-binding 
activity, we analyzed the promoter occupancy of c-Myb on the established target gene, MYC, 
using chromatin immunoprecipitation (ChIP). Neither the ANAA, nor the 2KR mutations, 
changed the ability of c-Myb to occupy the MYC promoter (Supplementary Figure 4). Together, 
this confirms a role for c-Myb SUMO binding in endogenous gene activation. 
 
c-Myb binds SUMO in trans in a SIM-dependent fashion 
Since our data obtained with double mutations and CRD-deletions did not support the hypothesis 
of intramolecular binding of SUMO, we predicted that the SIM had to bind SUMO in trans and 
that its repressive effect could be attributed to the recruitment of sumoylated, negatively acting 
co-factor(s). If so, it should be possible to titrate out this co-repressor with an excess of free 
SUMO, and thereby increase Myb activity. Thus, we expressed increasing amounts of non-
conjugatable SUMO1 and -2 (mono-Gly in C-terminal) in the presence of our c-Myb mutants. 
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We expected the non-conjugatable SUMO to interfere mainly with SUMO binding, but also 
indirectly with conjugation, since the conjugation process is dependent on SUMO interactions 
(Reverter and Lima 2005, Tatham et al 2005). As can be seen in Figure 6a, co-expression of 
SUMO1-1G in the presence of wild-type c-Myb led to an increase in transactivation, while no 
significant change in activity was seen for c-Myb ANAA 2KR. The derepression of wild-type c-
Myb was even more pronounced when titrating in increasing amounts of SUMO2-1G (Figure 
6b), consistent with the observed preference for SUMO2. Interestingly, a reduced responsiveness 
was observed for c-Myb ANAA as well as for c-Myb 2KR, indicating that both proteins are 
partly uncoupled from SUMO-mediated repression. For c-Myb ANAA the reduced 
responsiveness is most probably due to lost SUMO binding, while the residual induction may be 
caused by the SUMO-1Gs interfering with sumoylation. For the 2KR mutant the situation is 
reversed, and the remaining ability to be induced must be due to SUMO-1Gs titrating out SUMO- 
binding factors. 
As an alternative approach we also co-transfected our SUMO contact mutants together 
with plasmids expressing the SUMO-specific protease SENP1. The rationale was that SENP1 
would desumoylate both c-Myb and other (co-)factors. SENP1 would therefore relax both SUMO 
binding- and conjugation-dependent repression of c-Myb activity. As shown in Figure 6c co-
transfection led to an increase in activity for c-Myb wild-type, which was not seen with the 
catalytically dead SENP1 mutant. Moreover, both ANAA and 2KR mutants showed reduced 
potential for SENP1-induced activity. Importantly, only the double mutant, ANAA 2KR, was 
inert to the effects of desumoylation. Taken together these data strongly suggest that c-Myb binds 
SUMO in trans, probably in the form of a sumoylated co-repressor. This factor may be titrated 
out with free SUMO, with SUMO2 being the most efficient competitor due to its higher affinity 
for c-Myb. 
We also investigated whether broken SUMO contacts might change the distribution of c-
Myb. However, both in the absence and in the presence of PML IVa, a potential sumoylated co-
repressor, inducing PML NBs, neither loss of SUMO-binding, nor SUMO-conjugation properties 
affected the subcellular localization of c-Myb or its recruitment to PML-NBs (Supplementary 
Figure 5). 
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Proliferation and differentiation properties of the SUMO contact mutants 
To better understand the biological consequences of lost SUMO binding and conjugation, we 
investigated the transforming abilities of our c-Myb mutants. To this end we took advantage of a 
newly established murine hematopoietic cell line transformation assay (Pattabiraman et al 2009). 
FDB-1 is a factor-dependent cell line that proliferates in the presence of interleukin-3 (IL-3) and 
differentiates into granulocytes and macrophages within 7 days in the presence of granulocyte 
macrophage colony-stimulating factor (GM-CSF) (McCormack and Gonda 2000). c-Myb can, 
however, block GM-CSF-induced terminal differentiation of this cell line (Brown et al 2006), 
leading to continuous proliferation. We transduced FDB-1 cells with the GFP-tagged SUMO 
contact Myb mutants. The cells were then sorted for GFP expression before they were used to 
assay proliferation and differentiation properties. For control purposes the expression level and 
transactivational activity of the different Myb variants were validated by immunoblotting 
(Supplementary Figure 6) and effector-reporter assay (Supplementary Figure 7), respectively. 
As described before, cells transduced with wild-type c-Myb and c-Myb CT3 proliferated 
continuously in the presence of GM-CSF (Figure 7a). As expected, the empty vector-transduced 
cells lost their capacity to proliferate following stimulation with GM-CSF. Interestingly, the cells 
transduced with c-Myb ANAA and ANAA 2KR showed very rapid proliferation (with the latter 
reproducibly slightly higher than the former) compared to either wild-type or CT3 Myb, while the 
cells transduced with c-Myb 2KR behaved much like the wild-type Myb-transduced cells (Figure 
7a).  
To examine the effects of the SUMO contact mutants on differentiation of FDB-1 cells, 
we assessed morphology by May-Grunwald-Giemsa staining following culture in GM-CSF for 7 
days (Figures 7b and c). As reported earlier, c-Myb-transduced FDB-1 cells displayed a larger 
number of undifferentiated blast-like cells when compared empty vector-transduced cells (Figure 
7b). Myeloblasts made up approximately 30% of the cells with both c-Myb wild-type and CT3, 
representing a ten-fold increase compared to the empty vector control. An even more pronounced 
differentiation block with up to 50% blasts was seen with the SUMO binding mutants ANAA and 
ANAA 2KR, while the SUMO conjugation-dead 2KR mutant once again generated a 
differentiation profile similar to c-Myb wild-type (Figure 7b). We also assayed the expression of 
the myeloid cell surface differentiation markers Gr-1 and Mac-1. As seen in Figures 7d and e, 
and Supplementary Figure 8, FDB-1 cells transduced with the ANAA and ANAA 2KR mutants 
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showed lower expression of Gr-1 and Mac-1 compared to Myb wild-type, CT3, and 2KR. These 
differences were, however, not statistically significant, but consistent with the morphological data 
(Figure 7b). To confirm the results from the cell line transformation assays, colony-forming 
assays were conducted using primary hematopoietic cells from murine bone marrow. As shown 
in Figure 8, c-Myb wild-type transduced cells formed around 40 colonies per 50000 cells plated, 
whereas c-Myb ANAA and ANAA 2KR, as well as CT3, formed almost four-fold more. In 
contrast c-Myb 2KR behaved like the wild-type. These results are consistent with the results from 
FDB-1 assays. Taken together, the transformation assay data imply that the SUMO binding 
mutants ANAA and ANAA-2KR, but not the SUMO conjugation mutant 2KR, possess enhanced 
transforming activity compared to wild-type c-Myb. 
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DISCUSSION 
 
In this work we have identified a novel interaction of human c-Myb with SUMO, mediated by a 
SUMO-interacting motif (V267NIV) close to the transactivation domain. This motif is involved in 
regulating the transactivational potential as well as modulating the SUMO modification of c-
Myb. Most importantly, we show that SUMO binding is involved in dampening the transforming 
activity of this oncoprotein.  
The functionality of this motif was assessed by two criteria: (1) c-Myb should show 
detectable binding affinity for SUMO, dependent on an intact SIM; and (2) removal of SIM by 
mutation should cause a change in the activity of c-Myb. The first criterion was addressed by 
GST pull-down assays with different SUMO isoforms and showed that c-Myb binds SUMO in a 
SIM-dependent fashion, with a clear preference for SUMO2/3 (Figure 3). Secondly, mutation of 
the SIM substantially increased Myb’s transactivation potential (Figure 2). The determinant for 
SUMO isoform binding preference has been shown to lie in a stretch of negatively charged 
residues located directly N- or C-terminally of the SIM (Hecker et al 2006). Since the SIM in 
TAD only consisted of a hydrophobic core (closest acidic residue: +14), we reasoned that it 
would be a SUMO2/3-interacting motif, and indeed this was the case: In all the interaction assays 
we performed a preference for SUMO2 binding was observed (Figure 3). Still, SUMO1 binding 
might be functionally important when the modifier is conjugated to the appropriate factor, due to 
additional contact surfaces (Geiss-Friedlander and Melchior 2007).  
Our data may explain previous observations on the effect of linker insertion mutagenesis in 
AMV v-myb. In studies performed to examine the correlation between transactivation and 
transformation by v-Myb, Lane and co-workers in fact generated one insertion mutant interfering 
with the SIM element as defined in this work [v-Myb 752; I202NII→I202NGPII (Lane et al 1990)]. 
Interestingly, this mutant was able to activate transcription 25-fold more efficiently than AMV v-
Myb in QT6 cells (Chen and Lipsick 1993), suggesting that this might be due to loss of 
interaction with a unknown cellular inhibitor. In light of the present work their data may be 
explained by disruption of the SIM, hence SUMO binding. 
Mechanistically, we would assume that the SIM acts through the interaction with a 
sumoylated protein, exerting a repressive effect on c-Myb. The most obvious alternative would 
be an intermolecular mechanism, where a SUMO-modified co-repressor would bind to the SIM. 
An alternative hypothesis would be that the SIM interacts intramolecularly with sumoylated c-
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Myb CRD, leading to a repressed conformation of c-Myb. The second explanation would 
potentially substantiate the hypothesis of a fold-back mechanism involving the EVES domain and 
the N-terminal region in c-Myb (Dash et al 1996, Karafiat et al 2001) or the transactivation 
domain (Dubendorff et al 1992, Vorbrueggen et al 1994). Such intramolecular interactions have 
been hypothesized to conceal co-activator binding epitopes, thus lowering c-Myb activity. 
Indeed, the comparable activities of c-Myb 2KR and ANAA (Figures 2a and 5a) are consistent 
with a common mechanism, representing two ways of destroying the same intramolecular bridge. 
However, when introducing both mutations in the same construct, the transcriptional activity 
doubled (Figure 5a). Moreover, the ANAA mutant still activated when the CRD, including the 
SUMO-modified area of c-Myb, was deleted (Figure 5b). These data are not compatible with a 
SUMO-governed inhibitory fold-back mechanism in c-Myb, although they do not exclude the 
possibility of a fold-back mechanism not involving SUMO or not leading to activity changes. In 
light of these data it is interesting to notice that another type of crosstalk does occur. The SUMO-
interacting motif in the TAD is involved in fine tuning the sumoylation of c-Myb in the EVES 
domain, such that, mutating the SIM reduces the sumoylation of c-Myb slightly (Figure 4a). Such 
interdependency has been shown for other SUMO targets, and reflects the fact that non-covalent 
binding of SUMO is an important mechanistic step in the conjugation reaction, orientating the 
SUMO moiety for optimal transfer (Reverter and Lima 2005, Tatham et al 2005).  
Having ruled out the loss of intramolecular interaction as explanation of the increased 
transactivational activity of the SIM mutant, we addressed the possibility of intermolecular 
mechanisms. We reasoned that if a sumoylated factor was binding to c-Myb SIM, it should be 
possible to block this interaction by overexpressing non-conjugatable SUMO. Doing so we were 
able to increase the c-Myb activity, most likely by titrating out SUMO-binding repressors (Figure 
6: wt vs. ANAA) and also by decreasing conjugation of SUMO to the sites in CRD through 
interference with the sumoylation apparatus (Figure 6: wt vs. 2KR). Thus, c-Myb is repressed in 
trans via the SIM, as well as via the SUMO moieties in EVES. The identification of SUMO 
contact-dependent co-repressors will be addressed in future work. 
As the SUMO field has evolved, several diseases, including cancers, have been linked to 
perturbations in the SUMO system and/or disruption of sumoylation by mutations in substrate 
proteins (Hoeller et al 2006). Using hematopoietic transformation assays (Pattabiraman et al 
2009), we examined the transforming abilities of the SUMO interaction mutants. Interestingly, 
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only the SUMO binding ANAA mutant seemed to be able to transform hematopoietic cells more 
effectively than wild-type c-Myb (Figure 7 and 8). In contrast, the non-conjugatable c-Myb 2KR 
had the same transforming potential as wild-type Myb, despite both ANAA and 2KR mutants 
being similarly highly active in transactivation assays. Furthermore, the double mutant ANAA 
2KR was hyperactive in transactivation assays but was only marginally more active than ANAA 
in transforming the FDB1 cells (Figure 7). This is surprising because there is generally strong 
correlation between transactivation and transformation by c-Myb, e.g. (Hu et al 1991), and the 
importance of functional co-activation by CBP/p300 (Pattabiraman et al 2009) and  menin/MLL 
(Jin et al 2010) has been shown. In cancers linked to aberrations involving the MYB locus, 
increased c-Myb dosage, and hence activity, seem to be a common theme (Clappier et al 2007, 
Lahortiga et al 2007, Persson et al 2009). Nevertheless, the 2KR and ANAA mutants described 
here seem to partially dissociate transactivation from transformation. Even though both types of 
SUMO contacts appear to restrict c-Myb activity to the same degree, they clearly differ when it 
comes to restricting Myb-dependent transformation. Thus, the putative repressor interacting with 
the SIM in TAD must play a particularly important role. Interestingly, the two factors shown to 
be necessary for driving transformation by c-Myb, p300 and MLL (Jin et al 2010, Pattabiraman et 
al 2009), both bind within the same region. Thus, our data on SUMO binding adds to the 
complexity and functional importance of the transactivation domain in c-Myb. It is becoming 
increasingly apparent that this domain is a sophisticated control region in which the critical 
functions of c-Myb are regulated through a multiplicity of interactions, balancing activation and 
transformation. 
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MATERIALS AND METHODS 
 
Plasmids and antibodies 
Information about the plasmids and antibodies used in this work is outlined in Supplementary 
Information 
 
Protein expression and GST pull-down assay 
GST and GST-SUMO fusion proteins were expressed in E. coli as previously described 
(Gabrielsen et al 1991). GST pull-down was performed with both COS-1 expressed and in vitro 
translated proteins as described in Supplementary information. 
 
Cell culture and transfection, luciferase assays and immunoblotting 
COS-1 and CV-1 cells were grown as described (Andersson et al 2003). For details on luciferase 
assays and immunoblotting see Supplementary information. 
 
RNA Isolation and Quantitative Real-Time PCR  
Total RNA was extracted from transfected HD11 cells, reverse-transcribed and gene expression 
quantified as described in Supplementary Information  
 
In vitro transformation assay 
Assays were carried out as described in (Pattabiraman et al 2009) and as outlined in 
Supplementary Information 
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FIGURE LEGENDS 
 
Figure 1 c-Myb contains two putative SUMO-interacting motifs. (a) Schematic presentation of 
human c-Myb with its two potential SUMO-interacting motifs (SIMs), one residing in the R2 
repeat of DBD and the other in the N-terminal part of TAD. DBD: DNA-binding domain, TAD: 
transactivation domain, CRD: C-terminal regulatory domain, R1, -2, -3: Myb repeat 1, 2 and 3, 
TP/CR: Thr- and Pro-rich conserved region, FAETL and EVES: motifs found within the assigned 
regions, LZ: putative leucine zipper. (b) Multiple sequence alignment of the areas harbouring the 
putative SIMs (boxed), using different mammalian c-Mybs. The acidic stretches close to the 
motifs are indicated by a solid line. AMV v-Myb is included for comparison. SUMO-interacting 
consensus motifs are included for clarity (Hecker et al 2006, Song et al 2005). (c) The SIM 
mutants used in this work. No change in amino acid residue is marked with a hyphen.  
 
Figure 2 Destroying the putative SIM in the transactivation domain by mutations derepresses c-
Myb. (a) CV-1 cells were transfected with a Myb-responsive 3×MRE(GG)-MYC reporter 
plasmid (0.2 μg) and plasmids encoding full-length c-Myb wild-type, 2KR, AAEA, L106H, 
ANAA or INII in increasing amounts (0.2-0.4 μg).  The results are presented as relative 
luciferase units (RLU). The results represent the mean RLU±SEM of at least three independent 
assays performed in triplicates. (b) CV-1 cells were transfected with plasmids encoding c-Myb-
HA wild-type, 2KR, AAEA, L106H, ANAA or INII (0.2 μg). Cell lysates were subjected to 
SDS-PAGE and immunoblot analysis was performed using an anti-HA antibody. 
 
Figure 3 Human c-Myb binds SUMO via a SIM in the transactivation domain. In vitro binding 
assays were performed in lysates from COS-1 cells transfected with (a) FLAG-tagged wild-type 
c-Myb (aa 1-409), (b) wild-type c-Myb (aa 1-409) and the M1 mutants AAEA and L106H, (c) 
wild-type c-Myb (aa 1-409) and the M2 mutants ANAA and INII, and (d) full-length c-Myb (aa 
1-640), wild-type and ANAA. The lysate was incubated with comparable amounts of GST-
SUMO-1 and -SUMO2 fusion proteins. The bound proteins were analyzed by SDS-PAGE and 
immunoblot analysis using an anti-FLAG antibody. 5 % of the input (total cell extract) used for 
the pull-down was loaded as reference. The amount of GST and GST fusion proteins was 
evaluated with Ponceau S red staining of the membrane after immunoblotting. 
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Figure 4 Abrogating SUMO binding affects sumoylation of c-Myb. CV-1 cells were transfected 
with plasmids encoding c-Myb-HA wild-type, ANAA, INII or 2KR (1.0 μg) alone or in 
combination with a small input of Ubc9 or PIASy expression plasmid (0.25 μg). Cells were 
scraped in cold PBS and lysed directly by sonication in SDS loading-buffer. The lysates were 
subjected to SDS-PAGE and immunoblot analysis using an anti-HA antibody. PIASy was 
visualised using an anti-T7 antibody.  
 
Figure 5 Functional effects of altered SUMO interaction in the absence of SUMO conjugation. 
(a) CV-1 cells were transfected with a Myb-responsive 3×MRE(GG)-MYC reporter plasmid (0.2 
μg) and plasmids encoding full-length c-Myb wild-type, 2KR, ANAA or ANAA 2KR (0.4 μg). 
(b) CV-1 cells were transfected with a Myb-responsive 3×MRE(GG)-MYC reporter plasmid (0.2 
μg) and plasmids encoding  c-Myb[1-409] wild-type, ANAA or INII in increasing amounts (0.2-
0.4 μg). The results are presented as relative luciferase units (RLU). The results represent the 
mean RLU±SEM of at least three independent assays performed in triplicates. (c) Plasmids 
expressing c-Myb wild-type, 2KR, ANAA or ANAA 2KR were transfected into HD11 cells and 
total RNA was isolated. Activation of the endogenous Myb target gene, mim-1, was measured by 
quantitative real-time PCR using primers specific for the chicken mim-1 and HPRT genes. The 
results are presented as mim-1/HPRT expression, and normalized to the ratio in empty vector 
transfected cells (set to 1.0). The results represent the mean ± SEM of two independent biological 
assays, each analyzed in duplicates. Expression of the different c-Myb mutants were evaluated by 
immunoblotting performed with an anti-HA antibody. 
 
Figure 6 c-Myb is binding SUMO in trans in a SIM-dependent fashion.  CV-1 cells were 
transfected with a Myb-responsive 3×MRE(GG)-MYC reporter plasmid (0.2 μg) and plasmids 
encoding full-length c-Myb wild-type, ANAA, 2KR or ANAA 2KR (0.2 μg), in combination 
with increasing amounts (0-0.4 μg) of (a) SUMO1-1G or (b) SUMO2-1G (conjugation-deficient 
mutants). Increasing amounts of SUMO1-1G or SUMO2-1G (0–0.4 µg) were also transfected 
singularly together with the reporter. (c) c-Myb wild-type, ANAA, 2KR or ANAA 2KR (0.2 μg) 
were co-transfected with the SUMO protease SENP1 (0.2 μg) or SENP1 mutant (0.2 μg) as 
indicated. The results are presented as fold-induction of relative luciferase units (RLU), and the 
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activities of the different c-Myb proteins in the absence of SUMO is set to 1.0. The results 
represent the mean RLU±SEM of at least three independent assays performed in triplicates. 
 
Figure 7 Proliferation and differentiation properties of the SUMO contact mutants. FDB-1 cells 
were transduced with empty vector, c-Myb wild-type, CT3, ANAA, 2KR or ANAA 2KR and 
grown in medium containing IL-3. (a) 20.000 cells transduced with each mutant were seeded at 
day 0 and supplied with GM-CFS. Cells were then counted over a period of 8 days. The results 
represent the mean cell number ± SEM. Experiments were carried out in triplicate and repeated 
thrice with consistent results. (b) Transduced FDB-1 cells were grown in IL-3 and/or GM-CSF-
containing medium. After 7 days the cells were cytocentrifugated, the slides air-dried, fixed with 
methanol, and stained with May-Grunwald-Giemsa. (c) Approximately 500 cells per cytospin 
were scored based on their morphologic characteristics into myeloblasts, intermediate cells, and 
differentiated cells. Counts from at least three different cytospins were averaged. In addition  
1×106 FDB-1cells were cells were stained simultaneously with (d) anti-Gr-1 APC and (e) anti-
Mac-1 PE antibodies, washed, and fixed in 10% formalin. Stained cells were analyzed on a 
FACSCalibur flow cytometer. The results represent the mean value fluorescence ± SEM of three 
independent assays. 
 
Figure 8 Primary cell colony transformation assays of c-Myb SUMO contacts mutants. 
Transforming ability of the mutants was measured by colony formation. Hemopoietic cells were 
isolated from bone marrow of adult C57Bl/6 mice and transduced with empty vector, c-Myb 
wild-type, CT3, ANAA, 2KR or ANAA 2KR. Colonies consisting of >50 cells were counted. 
The results are shown as scatter plots, and the bars represent the mean number of colonies ± SD 
of three separate experiments, carried out in triplicate. 
 
 
 
 








